Search
Triptorelin
go.drugbank.com/drugs/DB06825ApprovedInvestigationalVet approvedTriptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous ad...
Products: POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial, Pamorelin Powder for Suspension for Injection 3.75 mgUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.
Categories: Biologics for psoriasis treatmentProducts: STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/26ML, STELARA 130mg/26mL Concentrate for Solution for InfusionAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.
Products: Zaltrap 25mg/ml Concentrate for Solution for Infusion, ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/MLSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG, KEVZARA Solution for Injection in Pre-filled Pen 150mgSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaProducts: LOKELMA POWDER FOR ORAL SUSPENSION 5G, LOKELMA POWDER FOR ORAL SUSPENSION 10GRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalVEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing
Products: CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML, CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)Atezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. … [L7489] In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program
Products: TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 840MG/14ML, Tecentriq 60mg/ml Concentrate for Solution for InfusionEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727].
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIALBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigationalIt is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.
Categories: Drugs for Obstructive Airway DiseasesProducts: Fasenra 30 mg solution for injection in pre-filled syringe, Fasenra 30mg Solution for Injection in Pre-filled Pen